Trial Profile
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- 12 Oct 2021 Status changed from suspended to discontinued.
- 14 Apr 2021 Planned End Date changed from 1 Jul 2021 to 1 Sep 2022.
- 14 Apr 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Sep 2022.